Tg Therapeutics Ord Shs (TGTX)
$21.00 0.20 (0.96%)
16:28 EDT TGTX Stock Quote Delayed 30 Minutes
Previous Close $21.00
Market Cap 1.64B
PE Ratio -10.61
Volume (Avg. Vol.) 1.12M
Day's Range 20.62 - 21.54
52-Week Range 4.95 - 24.76
Dividend & Yield N/A (N/A)
TGTX Stock Predictions, Articles, and Tg Therapeutics Ord Shs News
- From InvestorPlace
- From the Web
By Ian Cooper
With the worst of the coronavirus priced into markets, the U.S. economy is slowly reopening, serving as another boon for small-cap stocks.
These seven top stocks all boast substantial support from the Street. But that's not all ... they also have massive upside potential for the next few months, making these stocks a perfect choice to boost your 2018 portfolio performance.
Which stocks really blossomed in the first quarter of 2018? Here I single out the seven best-performing stocks of Q1 -- one from each sector. Looking forward, I turn to the Street to assess whether these seven picks still make compelling investing opportunities.
Here are five 'Strong Buy' biotech stocks with potential upside of over 100%. These five innovative stocks are worth tracking over the coming months according to the Street.
TG Therapeutics Inc (TGTX) shares skyrocketed more than 80% Monday as one of the company's drugs reached a new Phase III target and FDA approval may be next.
The overall ratings of 19 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Elevate Credit's (NYSE:ELVT) brand Rise enters into partnership with SpringFour, a social impact fintech company.Under the partnership, all Rise customers will gain access to SpringFour’s database of trusted local, state and national financial wellness resources.The services are available at no cost and will complement other free services such as financial literacy videos and credit monitoring.Source: Press Release
Navellier RatingsPowered by Portfolio Grader